COVID-19大流行背景下对英国胃肠病学会指南中急性重症溃疡性结肠炎管理的改编:RAND适宜性专家组
该研究采用RAND适宜性专家组方法,由14名胃肠病学家、1名IBD专科护士顾问及外科和COVID-19专家,以英国胃肠病学会(BSG)指南为参照,对COVID-19大流行期间急性重症溃疡性结肠炎(ASUC)的管理措施进行适宜性评分。专家组建议ASUC患者全程隔离、入院时行SARS-CoV-2拭子检测,拭子阳性者应与COVID-19专家讨论;初始管理按BSG指南使用静脉氢化可的松,仅COVID-19肺炎患者其使用被认定为不确定;需挽救治疗者推荐英夫利西单抗联合继续使用激素;因COVID-19推迟结肠切除术被认定为不适宜。
要点
- ASUC患者应全程隔离,入院时行SARS-CoV-2拭子检测,阳性者与COVID-19专家讨论。
- 静脉氢化可的松作为初始管理适宜,仅COVID-19肺炎患者其使用被认定为不确定。
- 需挽救治疗者推荐英夫利西单抗联合继续使用激素;因COVID-19推迟结肠切除术不适宜。
核心结论
- 作者利用RAND专家组提出了针对BSG ASUC指南的COVID-19特异性改编建议。
研究设计与样本
- RAND适宜性专家组,由14名胃肠病学家和1名IBD专科护士顾问组成,并辅以外科和COVID-19专家。
- 专家组成员在SARS-CoV-2感染背景下对ASUC干预措施的适宜性进行评分,计算中位评分和分歧指数(DI)。
- 结果在主持会议上讨论后进行第二次调查。
- 以当前BSG指南作为参照点提供COVID-19特异性指导。
主要发现
- 专家组推荐ASUC患者应全程隔离,并应在入院时进行SARS-CoV-2拭子检测。
- 拭子阳性的患者应与COVID-19专家讨论。
- 按照BSG指南,静脉氢化可的松被认为作为初始管理是适宜的;仅在有COVID-19肺炎的患者中,其使用被认为不确定。
- 在需要挽救治疗的患者中,推荐英夫利西单抗联合继续使用激素。
- 因COVID-19推迟结肠切除术被认为不适宜。
关键数值与推荐
- ASUC患者应全程隔离,并应在入院时进行SARS-CoV-2拭子检测。
- 拭子阳性的患者应与COVID-19专家讨论。
- 静脉氢化可的松作为初始管理是适宜的;仅在有COVID-19肺炎的患者中其使用被认为不确定。
- 在需要挽救治疗的患者中,推荐英夫利西单抗联合继续使用激素。
- 因COVID-19推迟结肠切除术被认为不适宜。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Management of acute severe UC (ASUC) during the novel COVID-19 pandemic presents significant dilemmas. We aimed to provide COVID-19-specific guidance using current British Society of Gastroenterology (BSG) guidelines as a reference point. DESIGN: We convened a RAND appropriateness panel comprising 14 gastroenterologists and an IBD nurse consultant supplemented by surgical and COVID-19 experts. Panellists rated the appropriateness of interventions for ASUC in the context of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Median scores and disagreement index (DI) were calculated. Results were discussed at a moderated meeting prior to a second survey. RESULTS: Panellists recommended that patients with ASUC should be isolated throughout their hospital stay and should have a SARS-CoV-2 swab performed on admission. Patients with a positive swab should be discussed with COVID-19 specialists. As per BSG guidance, intravenous hydrocortisone was considered appropriate as initial management; only in patients with COVID-19 pneumonia was its use deemed uncertain. In patients requiring rescue therapy, infliximab with continuing steroids was recommended. Delaying colectomy because of COVID-19 was deemed inappropriate. Steroid tapering as per BSG guidance was deemed appropriate for all patients apart from those with COVID-19 pneumonia in whom a 4-6 week taper was preferred. Post-ASUC maintenance therapy was dependent on SARS-CoV-2 status but, in general, biologics were more likely to be deemed appropriate than azathioprine or tofacitinib. Panellists deemed prophylactic anticoagulation postdischarge to be appropriate in patients with a positive SARS-CoV-2 swab. CONCLUSION: We have suggested COVID-19-specific adaptations to the BSG ASUC guideline using a RAND panel.
引用
- Din S, Kent A, Pollok RC, et al. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut. 2020. PMID: 32513653. doi:10.1136/gutjnl-2020-321927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。